Acrivon Therapeutics, Inc. (ACRV) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Acrivon Therapeutics reported revenue of $0. Net income was -$77.9M, or -$2.02 per diluted share. Operating activities generated -$63.7M of cash, leaving -$65.3M of free cash flow. At fiscal year end, Acrivon Therapeutics held $129.7M in total assets against $17.2M in total liabilities, including $41.5M of cash and equivalents.
Open the full interactive Acrivon Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Acrivon Therapeutics Key Stats
| Share Price | $1.75 |
|---|---|
| Market Cap | $73.2M |
| 52-Week Range | $1.29 – $3.01 |
| Shares Outstanding | 41.8 million (basic, 2026 Q2) |
Acrivon Therapeutics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$32.7M | -$67.1M | -$89.2M | -$84.1M |
| Pre-Tax Income | -$31.2M | -$60.4M | -$80.6M | -$77.8M |
| Income Tax | — | — | — | $0 |
| Net Income | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Diluted EPS | -$7.56 | -$2.74 | -$2.38 | -$2.02 |
Acrivon Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$18.2M | -$19.0M | -$19.0M | -$18.0M |
| Diluted EPS | -$0.47 | -$0.49 | -$0.49 | -$0.43 |
Acrivon Therapeutics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $29.5M | $36.0M | $39.8M | $41.5M |
| Current Assets | $132.1M | $129.7M | $181.6M | $120.4M |
| Total Assets | $181.2M | $138.3M | $196.6M | $129.7M |
| Current Liabilities | $6.5M | $13.3M | $17.2M | $15.7M |
| Total Liabilities | $10.8M | $17.1M | $19.8M | $17.2M |
| Shareholders' Equity | $170.5M | $121.2M | $176.8M | $112.5M |
Acrivon Therapeutics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$30.1M | -$42.6M | -$65.7M | -$63.7M |
| Cash From Investing | -$141.7M | $50.7M | -$51.8M | $66.1M |
| Cash From Financing | $101.7M | -$1.6M | $121.0M | -$749,000 |
| Free Cash Flow | -$32.3M | -$43.9M | -$68.4M | -$65.3M |
Figures from Acrivon Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Acrivon Therapeutics financials page for every line item.
Acrivon Therapeutics Company Profile
| Ticker | ACRV |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Watertown, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001781174 |
Frequently Asked Questions
What was Acrivon Therapeutics' revenue in fiscal 2025?
Acrivon Therapeutics (ACRV) reported revenue of $0 for fiscal 2025.
What is Acrivon Therapeutics' annual revenue history?
Acrivon Therapeutics' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Acrivon Therapeutics' net income in fiscal 2025?
Acrivon Therapeutics reported net income of -$77.9M for fiscal 2025.
What was Acrivon Therapeutics' earnings per share (EPS) in fiscal 2025?
Acrivon Therapeutics' diluted EPS was -$2.02 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Acrivon Therapeutics generate in fiscal 2025?
Acrivon Therapeutics generated -$65.3M of free cash flow in fiscal 2025.
What was Acrivon Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Acrivon Therapeutics reported revenue of $0.
How many shares of Acrivon Therapeutics are outstanding?
Acrivon Therapeutics reported a weighted average of 41.8 million basic shares outstanding in 2026 Q2.
What is Acrivon Therapeutics' market cap?
Based on its latest closing price, Acrivon Therapeutics (ACRV) has a market capitalization of about $73.2M.
When does Acrivon Therapeutics' fiscal year end?
Acrivon Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Acrivon Therapeutics headquartered?
Acrivon Therapeutics lists its business address in Watertown, Massachusetts in its SEC filings.